Maralixibat Clinical Trials

1 actively recruiting trial

No change since May 2026

Also known as: Formerly LUM001, SHP625, Livmarli Oral Solution, TAK-625

Top Sponsors

Takeda1

Indications

Alagille Syndrome (ALGS)1
Liver Disease1
Progressive Familial Intrahepatic Cholestasis (PFIC)1
Heart Disease1

Other1 trial

A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.